Receptor-Interacting Protein Kinase 1 (RIPK1) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting the necroptosis pathway—a programmed form of necrotic cell death that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related tauopathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD).
RIPK1 is a serine/threonine kinase that, when dysregulated, triggers necroptosis—a cell death pathway characterized by membrane rupture and release of pro-inflammatory intracellular contents (DAMPs). This leads to chronic neuroinflammation and progressive neuronal loss.
RIPK1 inhibitors work through multiple interconnected mechanisms:
flowchart TD
A["TNF-α<br/>Signaling"] --> B["TNFR1<br/>Complex I"]
B --> C{"RIPK1<br/>Kinase Activity"}
C -->|"Inhibited by<br/>RIPK1i"| D["NF-κB Survival<br/>Signaling"]
C -->|"Blocked"| E["Necrosome<br/>Formation"]
E --> F["RIPK1-RIPK3<br/>Interaction"]
F --> G["MLKL<br/>Phosphorylation"]
G --> H["Membrane<br/>Pore Formation"]
H --> I["Necrotic Cell<br/>Death"]
H --> J["DAMP Release"]
J --> K["Neuroinflammation"]
D --> L["Cell Survival"]
L --> M["Reduced<br/>Neuroinflammation"]
style I fill:#ff6b6b,stroke:#333
style K fill:#feca57,stroke:#333
style L fill:#c8e6c9,stroke:#333
- Kinase Domain Inhibition: Binding to the ATP-binding pocket of RIPK1, preventing autophosphorylation and activation
- Necrosome Disruption: Preventing RIPK1-RIPK3 interaction via RHIM domain inhibition
- Anti-inflammatory Effects: Blocking TNF-α-induced NF-κB activation in microglia and astrocytes
¶ Drug Candidates in Development
| Compound |
Developer |
Stage |
Key Features |
| GSK2982772 |
GlaxoSmithKline |
Phase 2 |
First-in-class oral RIPK1 inhibitor; proven safety in炎症 diseases |
| DNL747 (SAR443122) |
Denali Therapeutics/Sanofi |
Phase 2 |
Brain-penetrant; AD and ALS programs |
| R-705 |
Academic |
Preclinical |
Potent neuroprotective in animal models |
| PNK-787 |
Academic |
Preclinical |
Highly selective for RIPK1 |
Necrostatin-1 is a potent small-molecule inhibitor of RIPK1 kinase activity:
- Mechanism: Selectively inhibits RIPK1 autophosphorylation at Ser166
- Evidence in Neurodegeneration:
- ALS: Protected motor neurons in SOD1G93A mouse model through inhibition of TNF-α-mediated necroptosis
- AD: Reduced hippocampal neuronal loss and improved cognitive function in 5xFAD mice
- PD: Preserved dopaminergic neurons in MPTP mouse model
- HD: Improved survival and motor function in R6/2 Huntington's disease mice
Deguelin is a natural compound with potent RIPK1 inhibitory properties:
- Mechanism: Inhibits RIPK1 kinase activity and necrosome assembly
- Evidence in Neurodegeneration:
- ALS: Reduced motor neuron death in vitro and in vivo models
- PD: Protected against α-synuclein-induced toxicity
- AD: Attenuated amyloid-beta induced neuronal death
- Challenge: Limited brain penetration requires formulation optimization
A novel synthetic RIPK1 inhibitor with enhanced brain penetration:
- Mechanism: Covalent modification of RIPK1 kinase domain
- Evidence in Neurodegeneration:
- ALS: Demonstrated efficacy in patient-derived motor neuron models
- HD: Showed neuroprotective effects in striatal neuron cultures
RIPK1 activation in AD contributes to:
- Neuronal Death: Direct necroptosis of cortical and hippocampal neurons
- Neuroinflammation: DAMP release from necrotic neurons activates microglia
- Pathology Synergy: Aβ oligomers potentiate RIPK1 activation; RIPK1 promotes tau phosphorylation
Evidence Strength: Moderate — elevated RIPK1/RIPK3 in AD brain tissue, preclinical efficacy in multiple models
RIPK1 contributes to PD through:
- α-Synuclein Toxicity: Aggregated α-synuclein activates RIPK1 signaling
- Mitochondrial Dysfunction: PINK1/parkin dysfunction sensitizes neurons to necroptosis
- Microglial Activation: RIPK1 in substantia nigra microglia drives neuroinflammation
Evidence Strength: Moderate — RIPK1 inhibitors protect dopaminergic neurons in multiple models
RIPK1 activation is a prominent feature in ALS:
- Motor Neuron Degeneration: TNF-α-mediated necroptosis of upper and lower motor neurons
- Glial Cell Activation: Astrocytes and microglia show heightened RIPK1 signaling
- Protein Aggregate Stress: TDP-43 and SOD1 aggregates trigger RIPK1 activation
Evidence Strength: Strong — widespread RIPK1/RIPK3 activation in ALS patient spinal cord
RIPK1 contributes to HD through:
- Mutant Huntingtin Toxicity: mHTT promotes RIPK1 activation
- Striatal Vulnerability: Medium spiny neurons are particularly susceptible
- Energy Deficit: Mitochondrial dysfunction sensitizes to necroptosis
Evidence Strength: Emerging — growing evidence of RIPK1 involvement in HD pathogenesis
¶ CBS, PSP, and FTD
Chronic neuroinflammation is a common feature across tauopathies:
- CBS/PSP: Activated microglia show elevated RIPK1 expression; tau pathology associates with RIPK1 activation
- FTD: RIPK1 activation in cortical neurons correlates with TDP-43 and tau pathology
Biological Plausibility: Moderate — chronic neuroinflammation common to all three diseases provides rationale for RIPK1 inhibition
- Phase 1: Completed — favorable safety and pharmacokinetics
- Phase 2: Completed in psoriasis, ulcerative colitis, rheumatoid arthritis
- Neurodegeneration: No completed trials yet; serves as proof-of-concept for brain-penetrant development
- Phase 1: Completed SAD/MAD — demonstrated target engagement in peripheral blood mononuclear cells
- Phase 2: Planned for AD and ALS indications
- Key Feature: Designed for brain penetration with active transport via LRP1
- RIPK1 Inhibitors for ALS: Multiple academic groups planning Phase 1/2 trials
- Combination Approaches: RIPK1 inhibitors + anti-amyloid or anti-tau therapies in development
¶ Challenges and Limitations
- Blood-Brain Barrier Penetration: Many early inhibitors failed to achieve adequate brain concentrations
- Peripheral vs. Central Effects: Difficult to distinguish central from peripheral efficacy
- Long-term Safety: RIPK1 inhibition may impair immune surveillance against infections
- Patient Selection: Lack of validated biomarkers to identify patients with active necroptosis
- Timing of Intervention: Patients may need treatment before significant neuronal loss
- Translatability: Limited predictive validity of animal models
- Biomarker Development: Need for target engagement biomarkers in the brain
- Upstream Targeting: Blocks both cell death and neuroinflammation at their source
- Disease-Modifying Potential: Targets underlying mechanisms rather than symptoms
- Combination Therapy Potential: Synergy with amyloid, tau, or α-synuclein targeted approaches
- Cross-Disease Application: Single mechanism relevant to multiple neurodegenerative disorders
- Biomarker Development: PET ligands for necroptosis, blood-based RIPK1 activity assays
- Patient Stratification: Genetic and biomarker markers for necroptosis-prone subpopulations
- Combination Trials: RIPK1 inhibitors + standard of care for each indication